CLINICAL TRIALS PROFILE FOR NALTREXONE
✉ Email this page to a colleague
All Clinical Trials for naltrexone
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00000195 ↗ | Neurobiology of Opioid Dependence: 4 - 4 | Withdrawn | National Institute on Drug Abuse (NIDA) | Phase 2 | 1993-01-01 | The purpose of this study is to determine the effect of chronic naltrexone pre-treatment on the response to yohimbine in healthy volunteers. |
NCT00000195 ↗ | Neurobiology of Opioid Dependence: 4 - 4 | Withdrawn | Yale University | Phase 2 | 1993-01-01 | The purpose of this study is to determine the effect of chronic naltrexone pre-treatment on the response to yohimbine in healthy volunteers. |
NCT00000196 ↗ | Neurobiology of Opioid Dependence: 5 - 5 | Withdrawn | National Institute on Drug Abuse (NIDA) | Phase 2 | 1993-01-01 | The purpose of this study is to determine the effect of acute naltrexone pretreatment on the response to yohimbine in healthy volunteers. |
NCT00000196 ↗ | Neurobiology of Opioid Dependence: 5 - 5 | Withdrawn | Yale University | Phase 2 | 1993-01-01 | The purpose of this study is to determine the effect of acute naltrexone pretreatment on the response to yohimbine in healthy volunteers. |
NCT00000230 ↗ | Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 1995-01-01 | The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with naltrexone. |
NCT00000230 ↗ | Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12 | Completed | University of Vermont | Phase 2 | 1995-01-01 | The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with naltrexone. |
NCT00000231 ↗ | Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13 | Completed | University of Vermont | Phase 2 | 1992-02-01 | The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with pro-social activities. In addition, we will examine whether blind naltrexone dosing is effective in indicating naltrexone consumption. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for naltrexone
Condition Name
Clinical Trial Locations for naltrexone
Trials by Country
Clinical Trial Progress for naltrexone
Clinical Trial Phase
Clinical Trial Sponsors for naltrexone
Sponsor Name